67047-06-7

Basic information

• Product Name: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate
• Synonyms: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate
• CAS NO: 67047-06-7
• Molecular Weight: 444.441
• Mol File: 67047-06-7.mol

Chemical Properties

• CAS DataBase Reference: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate(67047-06-7)
• EPA Substance Registry System: 7-(benzyloxy)-4-oxo-2-phenyl-4H-1-benzopyran-5,6-diyl diacetate(67047-06-7)

Safety Data

• Hazardous Substances Data: 67047-06-7(Hazardous Substances Data)

Upstream product

• 491-67-8 5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one 
• 67047-05-6 4-oxo-2-phenyl-4H-1-benzopyran-5,6,7-triyl triacetate 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 

Downstream Products

• 74304-67-9 5,6-Diacetoxy-7-hydroxyflavon-7-O-(2,3,4-tri-O-acetyl-β-D-glucopyranosiduronsaeure-methylester) 
• 74293-55-3 5,6-Diacetoxy-7-hydroxyflavon-7-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosid) 
• 57396-78-8 Oroxin A 
• 21967-41-9 baicalin 
• 480-11-5 oroxylin A 
• 1357354-99-4 7-(benzyloxy)-5-hydroxy-4-oxo-2-phenyl-4H-1-benzopyran-6-yl 2-hydroxyacetate 
• 1357354-97-2 7-(benzyloxy)-6-(2-hydroxyethoxy)-5-methoxy-2-phenyl-4H-1-benzopyran-4-one 
• 1357354-95-0 7-(benzyloxy)-5-hydroxy-6-(2-hydroxyethoxy)-2-phenyl-4H-1-benzopyran-4-one 
• 1345982-19-5 5,7-dihydroxy-6-(2-morpholin-4-yl-ethoxy)-flavone 
• 1272971-84-2 5-hydroxy-6-(2-morpholin-4-yl-ethoxy)-7-benzyloxy-flavone 
• 5928-35-8 7-(benzyloxy)-5,6-dihydroxy-2-phenyl-4H-1-benzopyran-4-one 
• 67047-07-8 5,6-diacetoxy-7-hydroxyflavone 

Relevant articles and documents

Concise synthesis and antidiabetic activity of natural flavonoid glycosides, oroxins C and D, isolated from the seeds of Oroxylum indium

The first concise synthesis of natural flavonoid glycosides, oroxins C (1) and D (2), which were isolated from the seeds of Oroxylum indicum, was efficiently achieved by a convergent strategy. The synthesized natural products 1 and 2 were evaluated for th

Synthetic method of oroxylin

The invention relates to a synthetic method of oroxylin. The method disclosed by the invention comprises the following steps: carrying out acetylation reaction on 5, 6, 7-trihydroxy flavone and aceticanhydride in pyridine at room temperature; reacting an obtained acetylate with benzyl bromide or benzyl chloride in the presence of an inorganic base, and carrying out hydrolysis reaction on a product in alkaline water; and reacting with methyl iodide in the presence of an inorganic base, and finally debenzylating in the presence of concentrated sulfuric acid to obtain the target product oroxylin. The method for synthesizing oroxylin provided by the invention has the advantages of simple and feasible operation, high product purity, high reaction yield and the like, and is easier for industrial production compared with the existing method.

Novel synthetic baicalein derivatives caused apoptosis and activated AMP-activated protein kinase in human tumor cells

Studies on the anti-proliferative activities of novel baicalein derivatives demonstrated that compounds 8 and 9 were able to activate AMPK by enhancing the levels of phosphorylated AMPKα, and showed more potent anti-proliferative effects than baicalein an

Synthesis of ring A-modified baicalein derivatives

Baicalein, an important active constituent of the traditional Chinese herb Scutellaria baicalensis, exhibited antitumor activity and inhibitory activity against P-gp 170. The syntheses of 25 baicalein derivatives, 2-26 (Table), are described here (Scheme

COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING

The present invention is directed to analogs of baicalein according to formula (I): where R5 is H, (CI-C12)alkyl, (C2-C13)acyl, or an optionally substituted phenyl or benzyl group, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group; R6 and R7 are each independently H, (C1-C12)alkyl, (C2-C13)acyl, or an optionally substituted phenyl or benzyl or together form a -OCR1R20- group wherein each of R1 and R2 is independently H, a C1-C3 alkyl group or an optionally substituted phenyl or benzyl group; and R8 is H, OH, an O-acyl group, a C1,-C4 alkyl or alkoxy group, F, Cl, Br or I, or a pharmaceutically acceptable salt thereof, which exhibit anti-P-glycoprotein activity and methods of enhancing the bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme, especially CYP450 3A4 enzyme. Pharmaceutical compositions based upon these novel derivatives according to the present invention are also described herein.

Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring

The aqueous extract of Scutellariae baicalensis Georgi has inhibitory activity against P-gp 170, a multiple drug resistant gene product. Baicalein, one of the major flavones, was found to be responsible for this activity. The hydroxyl groups of the A ring

Synthese von Baicalin und einiger anderer Baicalein-glycoside

The 6- and 7-O-β-glucopyranosides 14 and 7 and the 6- and 7-O-β-glucopyranosiduronic acids 18 and 9 of baicalein (1) have been synthesized. 9 was identical with baicalin but 14 and tetuin, further 18 and a "baicalin-6-glucuronide" from Oroxylum indicum were different.